Baird raised the firm’s price target on Natera (NTRA) to $160 from $120 and keeps an Outperform rating on the shares. The firm said they reported 3Q revenue/gross margins, well ahead of estimates. Business momentum continued to be framed as broad based, including 60% year-over-year Signatera clinical volume growth and positive women’s health account wins.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: